Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 50

    1.

    The challenge of malaria eradication in the twenty-first century: research linked to operations is the key.

    Breman JG, Brandling-Bennett AD.

    Vaccine. 2011 Dec 30;29 Suppl 4:D97-103. Epub 2012 Jan 26.

    PMID:
    22284402
    [PubMed - in process]
    2.

    Geographic differentiation of polymorphism in the Plasmodium falciparum malaria vaccine candidate gene SERA5.

    Tanabe K, Arisue N, Palacpac NM, Yagi M, Tougan T, Honma H, Ferreira MU, Färnert A, Björkman A, Kaneko A, Nakamura M, Hirayama K, Mita T, Horii T.

    Vaccine. 2012 Feb 21;30(9):1583-93. Epub 2012 Jan 9.

    PMID:
    22230587
    [PubMed - in process]
    3.

    The effect of adjuvants on the immune response induced by a DBL4ɛ-ID4 VAR2CSA based Plasmodium falciparum vaccine against placental malaria.

    Pinto VV, Salanti A, Joergensen LM, Dahlbäck M, Resende M, Ditlev SB, Agger EM, Arnot DE, Theander TG, Nielsen MA.

    Vaccine. 2012 Jan 11;30(3):572-9. Epub 2011 Nov 26.

    PMID:
    22122859
    [PubMed - indexed for MEDLINE]
    4.
    5.

    A polyvalent hybrid protein elicits antibodies against the diverse allelic types of block 2 in Plasmodium falciparum merozoite surface protein 1.

    Tetteh KK, Conway DJ.

    Vaccine. 2011 Oct 13;29(44):7811-7. Epub 2011 Aug 4.

    PMID:
    21820475
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    6.

    Immunization with the RTS,S/AS malaria vaccine induces IFN-γ(+)CD4 T cells that recognize only discrete regions of the circumsporozoite protein and these specificities are maintained following booster immunizations and challenge.

    Schwenk R, Lumsden JM, Rein LE, Juompan L, Kester KE, Heppner DG, Krzych U.

    Vaccine. 2011 Nov 8;29(48):8847-54. Epub 2011 Oct 5.

    PMID:
    21983360
    [PubMed - indexed for MEDLINE]
    7.

    Immunogenicity of novel nanoparticle-coated MSP-1 C-terminus malaria DNA vaccine using different routes of administration.

    Cherif MS, Shuaibu MN, Kurosaki T, Helegbe GK, Kikuchi M, Yanagi T, Tsuboi T, Sasaki H, Hirayama K.

    Vaccine. 2011 Nov 8;29(48):9038-50. Epub 2011 Sep 20.

    PMID:
    21939717
    [PubMed - indexed for MEDLINE]
    8.

    Malaria vaccine candidate: design of a multivalent subunit α-helical coiled coil poly-epitope.

    Olugbile S, Villard V, Bertholet S, Jafarshad A, Kulangara C, Roussilhon C, Frank G, Agak GW, Felger I, Nebie I, Konate K, Kajava AV, Schuck P, Druilhe P, Spertini F, Corradin G.

    Vaccine. 2011 Sep 16;29(40):7090-9. Epub 2011 Jul 29.

    PMID:
    21803099
    [PubMed - indexed for MEDLINE]
    9.

    Comparative efficacy of pre-erythrocytic whole organism vaccine strategies against the malaria parasite.

    Friesen J, Matuschewski K.

    Vaccine. 2011 Sep 16;29(40):7002-8. Epub 2011 Jul 23.

    PMID:
    21787828
    [PubMed - indexed for MEDLINE]
    10.

    Cellular and humoral immune effector mechanisms required for sterile protection against sporozoite challenge induced with the novel malaria vaccine candidate CelTOS.

    Bergmann-Leitner ES, Legler PM, Savranskaya T, Ockenhouse CF, Angov E.

    Vaccine. 2011 Aug 11;29(35):5940-9. Epub 2011 Jun 29.

    PMID:
    21722682
    [PubMed - indexed for MEDLINE]
    11.

    Plasmodium falciparum serine repeat antigen 5 (SE36) as a malaria vaccine candidate.

    Palacpac NM, Arisue N, Tougan T, Ishii KJ, Horii T.

    Vaccine. 2011 Aug 11;29(35):5837-45. Epub 2011 Jun 28. Review.

    PMID:
    21718740
    [PubMed - indexed for MEDLINE]
    12.

    Worldwide sequence conservation of transmission-blocking vaccine candidate Pvs230 in Plasmodium vivax.

    Doi M, Tanabe K, Tachibana S, Hamai M, Tachibana M, Mita T, Yagi M, Zeyrek FY, Ferreira MU, Ohmae H, Kaneko A, Randrianarivelojosia M, Sattabongkot J, Cao YM, Horii T, Torii M, Tsuboi T.

    Vaccine. 2011 Jun 10;29(26):4308-15. Epub 2011 Apr 21.

    PMID:
    21514344
    [PubMed - indexed for MEDLINE]
    13.

    A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine.

    Porter DW, Thompson FM, Berthoud TK, Hutchings CL, Andrews L, Biswas S, Poulton I, Prieur E, Correa S, Rowland R, Lang T, Williams J, Gilbert SC, Sinden RE, Todryk S, Hill AV.

    Vaccine. 2011 Oct 6;29(43):7514-22. Epub 2011 Apr 16.

    PMID:
    21501642
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    14.

    Four year immunogenicity of the RTS,S/AS02(A) malaria vaccine in Mozambican children during a phase IIb trial.

    Aide P, Dobaño C, Sacarlal J, Aponte JJ, Mandomando I, Guinovart C, Bassat Q, Renom M, Puyol L, Macete E, Herreros E, Leach A, Dubois MC, Demoitie MA, Lievens M, Vekemans J, Loucq C, Ballou WR, Cohen J, Alonso PL.

    Vaccine. 2011 Aug 11;29(35):6059-67. Epub 2011 Apr 7.

    PMID:
    21443960
    [PubMed - indexed for MEDLINE]
    15.

    Long term stability of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Montanide(®) ISA 720 and stabilized with glycine.

    Zhu D, McClellan H, Dai W, Gebregeorgis E, Kidwell MA, Aebig J, Rausch KM, Martin LB, Ellis RD, Miller L, Wu Y.

    Vaccine. 2011 May 9;29(20):3640-5. Epub 2011 Apr 8.

    PMID:
    21440641
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    16.

    Effect of nanoparticle coating on the immunogenicity of plasmid DNA vaccine encoding P. yoelii MSP-1 C-terminal.

    Shuaibu MN, Cherif MS, Kurosaki T, Helegbe GK, Kikuchi M, Yanagi T, Sasaki H, Hirayama K.

    Vaccine. 2011 Apr 12;29(17):3239-47. Epub 2011 Feb 26.

    PMID:
    21354479
    [PubMed - indexed for MEDLINE]
    17.

    A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2--a GLURP-MSP3 fusion protein malaria vaccine candidate.

    Lousada-Dietrich S, Jogdand PS, Jepsen S, Pinto VV, Ditlev SB, Christiansen M, Larsen SO, Fox CB, Raman VS, Howard RF, Vedvick TS, Ireton G, Carter D, Reed SG, Theisen M.

    Vaccine. 2011 Apr 12;29(17):3284-92. Epub 2011 Feb 22.

    PMID:
    21349366
    [PubMed - indexed for MEDLINE]
    18.

    Adenovirus particles that display the Plasmodium falciparum circumsporozoite protein NANP repeat induce sporozoite-neutralizing antibodies in mice.

    Palma C, Overstreet MG, Guedon JM, Hoiczyk E, Ward C, Karen KA, Zavala F, Ketner G.

    Vaccine. 2011 Feb 11;29(8):1683-9. Epub 2011 Jan 1.

    PMID:
    21199707
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    19.

    Adenovirus-vectored Plasmodium vivax ookinete surface protein, Pvs25, as a potential transmission-blocking vaccine.

    Miyata T, Harakuni T, Sugawa H, Sattabongkot J, Kato A, Tachibana M, Torii M, Tsuboi T, Arakawa T.

    Vaccine. 2011 Mar 24;29(15):2720-6. Epub 2011 Feb 11.

    PMID:
    21315699
    [PubMed - indexed for MEDLINE]
    20.

    Towards validated assays for key immunological outcomes in malaria vaccine development.

    OPTIMALVAC consortium, Cavanagh DR, Dubois PM, Holtel A, Kisser A, Leroy O, Locke E, Moorthy VS, Remarque EJ, Shi YP.

    Vaccine. 2011 Apr 12;29(17):3093-5. Epub 2011 Feb 4. No abstract available.

    PMID:
    21296116
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk